ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 41773262

Fibroblast Growth Factor Receptor (FGFR) Inhibitors for the Treatment of Cholangiocarcinoma: Key Therapeutic Developments and Knowledge Gaps.

Erul E and 7 others. Drug Des Devel Ther, 2026. Cited by 1 paper, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Fibroblast Growth Factor Receptor (FGFR) Inhibitors for the Treatment of Cholangiocarcinoma: Key Therapeutic Developments and Knowledge Gaps. Papers, record 41773262. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41773262

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Fibroblast Growth Factor Receptor (FGFR) Inhibitors for the Treatment of Cholangiocarcinoma: Key Therapeutic Developments and Knowledge Gaps.
PubMed
Journal
Drug Des Devel Ther
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-08-13
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Erul EEnes
2Cifuentes-Canaval SSergiohttps://orcid.org/0000-0002-8847-3392
3Santhosh AAkhil
4Sokolović EEmirhttps://orcid.org/0000-0001-7015-7378
5Della Mura MMario
6Cazzato GGerardo
7Kubilay Tolunay PPınar
8Rizzo AAlessandro

Source PubMed

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CholangiocarcinomaMajor topic
Protein Kinase InhibitorsMajor topic
Bile Duct NeoplasmsMajor topic
Receptors, Fibroblast Growth FactorMajor topic
Receptor, Fibroblast Growth Factor, Type 2Major topic
Antineoplastic AgentsMajor topic
Humans
Animals

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References80

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128,303,906Advances and challenges in targeting FGFR signalling in cancer.Nat Rev Cancer2017https://conductscience.org/library/papers/28303906PubMed
231,340,094Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.N Engl J Med2019https://conductscience.org/library/papers/31340094PubMed
338,206,555Pemigatinib: A Review in Advanced Cholangiocarcinoma.Target Oncol2024https://conductscience.org/library/papers/38206555PubMed
434,199,304FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice.Cancers (Basel)2021https://conductscience.org/library/papers/34199304PubMed
527,000,463Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise.Oncologist2016https://conductscience.org/library/papers/27000463PubMed
640,205,008FGFR as a Predictive Marker for Targeted Therapy in Gastrointestinal Malignancies: A Systematic Review.J Gastrointest Cancer2025https://conductscience.org/library/papers/40205008PubMed
736,900,367Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the 'NSCLC' of GI Oncology?Cancers (Basel)2023https://conductscience.org/library/papers/36900367PubMed
835,544,727Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response.JCO Precis Oncol2022https://conductscience.org/library/papers/35544727PubMed
936,497,187FGFR Inhibitors in Cholangiocarcinoma-A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis?Cells2022https://conductscience.org/library/papers/36497187PubMed
1035,092,702Population Pharmacokinetics Analysis of Pemigatinib in Patients With Advanced Malignancies.Clin Pharmacol Drug Dev2022https://conductscience.org/library/papers/35092702PubMed

1 to 10 of 80

See all 80 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

None in this release.

Genes42

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AHCYL110,768PubTator's text mininghttps://conductscience.org/library/genes/10768NCBI Gene
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
BAP18,314PubTator's text mininghttps://conductscience.org/library/genes/8314NCBI Gene
BICC180,114PubTator's text mininghttps://conductscience.org/library/genes/80114NCBI Gene
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CDKN2B1,030PubTator's text mininghttps://conductscience.org/library/genes/1030NCBI Gene
CEP5555,165PubTator's text mininghttps://conductscience.org/library/genes/55165NCBI Gene
CSF1R1,436PubTator's text mininghttps://conductscience.org/library/genes/1436NCBI Gene

1 to 10 of 42

See all 42 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41773262

GET https://conductscience.org/api/papers/v1/41773262/references?page=2

API referenceFor AI assistants